TO THE EDITOR
Fms-like tyrosine kinase 3 (FLT3) is a member of the class III receptor tyrosine kinase subfamily and plays an important role in the proliferation of hematopoietic progenitors. The internal tandem duplications (ITDs) in the juxtamembrane (JM) domain of FLT3 are demonstrated in approximately 20% of acute myeloblastic leukemia (AML) patients. FLT3-ITDs are associated with increased leukocyte counts and are more prevalent in AML patients with normal karyotype. Furthermore, FLT3-ITDs are associated with high relapse rate in patients with AML. In addition, substitution mutations in the second tyrosine kinase (TK2) domain at D835 of the FLT3 gene have recently been reported in approximately 7% of patients with AML.
1,2 Both the FLT3-ITD and FLT3-D835 mutations result in constitutive activation of the receptor that probably confers a proliferative benefit to AML cells with ligand-independent dimerization, autophosphorylation and activation of downstream pathways. As FLT3 mutations have been implicated in the pathogenesis of AML and are potential therapeutic targets for specific tyrosine kinase inhibitors, a complete characterization of FLT3 mutations would be necessary.
FLT3-D835/I836 mutations were intensively examined by restriction fragment length polymorphism-mediated PCR assay using EcoRV.
1 However, this screening cannot detect other mutations in the activation loop of the FLT3 gene. In this study, we searched for novel mutations in the activation loop of the FLT3 gene in 172 untreated patients with de novo AML using nonisotopic RNase cleavage assay (NIRCA). Informed consent to use the samples for this study was NIRCA was performed using the MutationScreener Kit (Ambion, Austin, TX, USA). The second PCR products were converted to RNA by transcription with T7 polymerase. Each RNA strand was hybridized with the transcript from the wild-type cDNA, cleaved with RNase1, and electrophoresed in 2.5% agarose gels. The NIRCA could detect a single-base mutation in the TK2 domain of the FLT3 gene when leukemic cells carrying a mutation were present in 5% of the test samples (Supplementary Figure 1) . To ascertain whether the mutations were at D835 or I836, the second PCR products were digested by EcoRV (TaKaRa, Otsu, Japan) and subjected to electrophoresis, as described previously. 3 For sequencing, cDNA was amplified by PCR to produce 480 bp products using primers FL-MF4, 5
0 -CAA ATTCCAGCATGCCTGGTTCA-3 0 (2198-2220), and FL-MR2, 5 0 -GAATGCCAGGGTAAGGATTCACA-3 0 (2677-2655). The PCR products were subcloned into plasmid pGEM-T Easy vector (Promega Co, Madison, WI, USA) and subjected to cycle sequencing (Applied Biosystems, Foster City, CA, USA).
Of 172 patients with newly diagnosed AML examined for activating loop mutations in the FLT3 gene by NIRCA, 16 (9.3%) showed positive results. For patients with positive results, the reproducibility of NIRCA was confirmed by experiments performed at least twice. Subsequently, we performed EcoRV digestion of the NIRCA-positive-PCR products. A total of 15 patients generated nondigested band and confirmed the presence of the mutations at D835 or I836 by sequencing. One patient with M2 and t(8;21) showed positive for NIRCA (Figure 1b) , and negative for EcoRV digestion (Figure 1c) . RT-PCR was repeated using different cDNA from this patient, and gave the same results.
Sequence analysis revealed that the third nucleotide C of N841 was substituted with A, resulting in an Asn to Lys amino-acid change (N841 K), in three of seven clones sequenced (Figure 1d ). Interestingly, a C-KIT-activating mutation N822K was found in Kasumi-1 leukemia cell line with t(8;21). 4 This observation may support that N841K in FLT3 would also be an activating mutation, because N822 of C-KIT is equivalent to N841 of FLT3.
Recently, a series of novel mutations within the activation loop of the FLT3 gene were identified in patients with AML. A 6 bp insertion in the activation loop between codons 840 and 841 of FLT3 (FLT3-840GS) was found in two of 359 patients with AML. 5 This mutation represents an activating mutation in functional analyses. Furthermore, Jiang et al 6 identified novel point mutations, N841I and N841Y. N841I was experimentally shown to generate an active protein. On the other hand, Stirewalt et al 7 identified novel missense point mutations in the JM domain of FLT3 by using single-stranded conformational polymorphism analysis in patients with AML. In addition, a missense mutation in the first tyrosine kinase (TK1) domain (A680V) of the FLT3 gene was detected in an AML patient by using denaturing high-performance liquid chromatography. 8 Together with our study, these observations suggest that additional investigations of the FLT3 mutations should be performed in AML. To date, several FLT3 inhibitors were shown to be sensitive toward FLT3-activating mutations. Although N841 mutations seem to be rare events, it will be useful to determine the exact kind of mutation in AML patients who might get benefit from new targeted therapy. 
